Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3534 Phase 1 Study in Healthy Male Volunteers
NCT06482346Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in rheumatoid arthritis (RA) comparing MT-3534 with Placebo (2 arms). Primary endpoints: Number of subjects with adverse events at Day 85, Number of subjects with adverse reactions at Day 85 and 1 more. Started Aug 2024; status: completed.
02
Drugs
MT-3534
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06482346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06482346.